Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by MrMugsyon Feb 22, 2021 4:46pm
201 Views
Post# 32629417

RE:Q4 - Quarterly - Delayed Last Year

RE:Q4 - Quarterly - Delayed Last Year
schocor wrote: I have no insight into when the Q4 financials will be out. I know March 30th was last year, but they were delayed (buy 2-3 weeks?). I am thinking early to mid March for his year. A word on what they MIGHT use an equity financing for would be nice - but maybe a little for that kind of news. I think I will take a starter position on this stock this week and am hoping for 5.25ish entry point.


Hello Schocor.
You are right on your observation ... but I don't think he's had much to say for a long while - hahaha!

Anyway, I have a bunch of questions for the company.  Will let you know if I learn anything on the plans for financing.

Keep in mind that it's probably just good planning to have the shelf prospectus ready to go.  Goodman prides himself on always going to market at higher valuations so I wouldn't expect it happens under $12 (or so).

They have lots of cash to use right now.

The only time I see GUD going to market below the last offer price would be related to all the stars lining up imperfectly ... and all requiring cash now ...
- A deal with existing partners in new geographies that is time sensitive
- A deal or deals in Mexico that need to close immediately or we could lose them
- Rolling out TUSLA across Canada
- Acquisitions in South Africa or other ROW countries that are too good to overlook

The more likely scenario will see a few deals occur while LATAM is optimized, causing the share price to return to higher levels (~$12+) and then cashing up to be in acquisition mode again.  The window is so big that any of it could happen over the next 2.5 years.

All in my opinion.


<< Previous
Bullboard Posts
Next >>